<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550027</url>
  </required_header>
  <id_info>
    <org_study_id>R 574/17 - IEO 607</org_study_id>
    <nct_id>NCT03550027</nct_id>
  </id_info>
  <brief_title>Indwelling Pleural Catheter for Trapped Lung</brief_title>
  <official_title>Indwelling Pleural Catheter for Trapped Lung: a Pilot Study for Power Calculation of a Randomized Controlled Trial Comparing Pleurocath速 Versus PleurX速)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural effusion (MPE) is a complication of almost any site of primary cancer as
      well as primary tumors of the pleura. Half of MPE patients have non-expendable trapped lungs
      not suitable for talc pleurodesis. Indwelling pleural catheters (IPCs), however, can be used
      in this cohort of patients, bringing about an improvement in dyspnea and quality of life
      (QOL).

      The aim of this study is to obtain pilot data - comparing patients receiving two different
      types of indwelling pleural catethers normally used in clinical practice (10 patients
      receiving Pleurocath速 and 10 patients receiving PleurX速) - for power calculation of a
      Randomized Controlled Trial comparing two different drainages for MPE trapped lung.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Actual">February 15, 2018</completion_date>
  <primary_completion_date type="Actual">November 3, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) range 0 (no pain) - 100 (maximum pain)</measure>
    <time_frame>Post operative day 4th</time_frame>
    <description>Thoracic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) range 0 (no dyspnea) - 100 (maximim dyspnea)</measure>
    <time_frame>Post operative day 4th</time_frame>
    <description>Dyspnea</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pleura; Effusion</condition>
  <arm_group>
    <arm_group_label>PleurX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positioning of Pleurx drainage during surgical exploration if lung does not reinflate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pleurocath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PleurX</intervention_name>
    <description>Positioning of drainage PleurX</description>
    <arm_group_label>PleurX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pleurocath</intervention_name>
    <description>Positioning of drainage Pleurocath</description>
    <arm_group_label>Pleurocath</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, with a clinical confident diagnosis of symptomatic malignant pleural
             effusion, enrolled for VATS exploration but not amenable of VATS talc poudrage because
             of trapped lung (patients with only partial expansion however receiving talc poudrage,
             but needing permanent pleural cathetes, are also eligible)

        Exclusion Criteria:

          -  - Age younger than 18 years

          -  Expected survival of less than 3 months

          -  Chylothorax

          -  Total white blood cell count less than 1000/microL

          -  Pregnancy or lactating mothers

          -  Irreversible bleeding diathesis

          -  Irreversible visual impairment

          -  Contraindications to general anesthesia

          -  Poor general clinical conditions ( ECOG PS &gt;=2)

          -  Patients unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Petrella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>European Institute of Oncology</investigator_affiliation>
    <investigator_full_name>Francesco Petrella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

